Latest news with #USFDA-approved
Economic Times
3 days ago
- Business
- Economic Times
Carlyle portfolio firms SeQuent Scientific and Viyash Life get stock exchange nod for merger
SeQuent and Viyash move a step closer to merging, with Carlyle aiming to build a 2X scale business in animal health and pharma R&D. Carlyle-backed SeQuent Scientific and Viyash Life Sciences have secured stock exchange approvals for their merger. Next, they will approach NCLT. The merged entity aims to double in scale, with SeQuent's animal health focus complemented by Viyash's R&D and API strengths. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Carlyle portfolio firms SeQuent Scientific and Viyash Life Sciences have got stock exchange approvals for their planned merger. The former is listed while the latter is Scientific conveyed the development in a stock exchange filing on a next step, they will approach the national company law tribunal (NCLT) for holds a 53% stake in SeQuent and is the majority shareholder in privately held Viyash. SeQuent operates in the niche segment of Animal Health and markets its products in over 90 has built a strong presence in active pharmaceutical ingredients (API) and R&D space with strong business relations with leading companies around the globe.'We are pleased that our proposed merger with Viyash Life Sciences is progressing as planned. This merger will accelerate a compelling new journey for SeQuent as a leading player in animal health, and Viyash with its world-class R&D capabilities and USFDA-approved facilities,' said Rajaram Narayanan, managing director, SeQuent Scientific.'FY 2024–25 marks a pivotal year for us, with strong business results as we accelerate our growth and lay the foundation for the next phase of growth. With Viyash joining us, we are poised to become a significantly stronger business—2X in scale, capability, and opportunity.'Under the agreed merger terms, shareholders of Viyash will receive 56 SeQuent shares for every 100 Viyash shares Q4 FY25, the combined entity of SeQuent and Viyash delivered robust performance with consolidated revenues of Rs. 770 crore reflecting a 13.2% year-on-year growth. Adjusted earnings before interest, tax, depreciation and amortization stood at Rs. 122 crore, up 63.2%, with margins expanding by 485 basis points to 15.8%.
Time of India
3 days ago
- Business
- Time of India
Carlyle portfolio firms SeQuent Scientific and Viyash Life get stock exchange nod for merger
Carlyle portfolio firms SeQuent Scientific and Viyash Life Sciences have got stock exchange approvals for their planned merger. The former is listed while the latter is not. SeQuent Scientific conveyed the development in a stock exchange filing on Thursday. As a next step, they will approach the national company law tribunal (NCLT) for approval. Carlyle holds a 53% stake in SeQuent and is the majority shareholder in privately held Viyash. SeQuent operates in the niche segment of Animal Health and markets its products in over 90 countries. Viyash has built a strong presence in active pharmaceutical ingredients (API) and R&D space with strong business relations with leading companies around the globe. 'We are pleased that our proposed merger with Viyash Life Sciences is progressing as planned. This merger will accelerate a compelling new journey for SeQuent as a leading player in animal health, and Viyash with its world-class R&D capabilities and USFDA-approved facilities,' said Rajaram Narayanan, managing director, SeQuent Scientific. 'FY 2024–25 marks a pivotal year for us, with strong business results as we accelerate our growth and lay the foundation for the next phase of growth. With Viyash joining us, we are poised to become a significantly stronger business—2X in scale, capability, and opportunity.' Under the agreed merger terms, shareholders of Viyash will receive 56 SeQuent shares for every 100 Viyash shares held. In Q4 FY25, the combined entity of SeQuent and Viyash delivered robust performance with consolidated revenues of Rs. 770 crore reflecting a 13.2% year-on-year growth. Adjusted earnings before interest, tax, depreciation and amortization stood at Rs. 122 crore, up 63.2%, with margins expanding by 485 basis points to 15.8%.
United News of India
20-05-2025
- Business
- United News of India
Torrent Pharma Q4 revenue pc, net profit rises 11 pc
Ahmedabad, 20 May (UNI) Torrent Pharmaceuticals Limited on Tuesday announced its financial results for the fourth quarter and full year ended 31 March 2025, reporting steady growth across key metrics. For Q4 FY25, the company posted revenue of Rs 2,959 crore, marking an 8 percent year-on-year increase. Gross margin remained stable at 75.3 percent. Operating EBITDA rose 9 percent to Rs. 964 crore, while net profit after tax climbed 11 percent to Rs. 498 crore. Adjusted for exceptional items and inventory revaluation, operating EBITDA stood at Rs. 981 crore, an 11 percent rise. For the full fiscal year, Torrent reported revenues of Rs 11,516 crore, up 7 percent from the previous year. Operating EBITDA grew 10 percent to Rs. 3,721 crore, with net profit reaching Rs 1,911 crore, reflecting a 15 percent increase after adjustments for exceptional items. The company's India business continued its robust performance with Q4 revenues of Rs 1,545 crore, growing 12 percent and outperforming the Indian Pharmaceutical Market (IPM) growth of 8 percent. Torrent's chronic therapy segment expanded 14 percent compared to 9 percent IPM growth. The company holds 21 brands in the Top 500 IPM brands, including 14 brands with sales exceeding Rs 100 crore. In Brazil, revenues declined 6 percent to Rs. 351 crore, primarily due to the depreciation of the Brazilian Real. However, constant currency revenues increased by 5 percent. Torrent's Brazil operations grew 13 percent compared to a 7 percent market growth. Germany revenues rose 2 percent to Rs. 286 crore, supported by new tender wins and cost efficiency initiatives. The US market recorded a 15 percent revenue growth in Q4 to Rs. 302 crore, with constant currency growth at 10 percent. Torrent has declared an interim dividend of Rs. 26 per equity share (face value Rs. 5). The Board has recommended a final dividend of Rs. 6 per share, subject to shareholders' approval. In a strategic leadership move, Torrent's Board approved the appointment of Aman Mehta as Managing Director, effective 1 August 2025, as part of its long-term succession planning. Torrent Pharmaceuticals, the flagship entity of the Torrent Group, ranks seventh in the Indian pharmaceutical market and holds leadership positions in cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology segments. The company operates in over 50 countries, runs eight manufacturing facilities including five USFDA-approved plants, and maintains a strong focus on R&D with over 750 scientists. UNI BDN GNK
Business Upturn
20-05-2025
- Business
- Business Upturn
Senores Pharmaceuticals acquires USFDA-approved ANDA for Enalapril Maleate Tablets from Wockhardt
By Aman Shukla Published on May 20, 2025, 15:47 IST Senores Pharmaceuticals Limited (SPL), through its wholly-owned US subsidiary, Senores Pharmaceuticals, Inc. (SPI), has entered into an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg. The ANDA is being acquired from Wockhardt Limited. Enalapril Maleate is a generic pharmaceutical product indicated for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is a widely prescribed medication in cardiovascular therapy. According to IQVIA, the U.S. market size for Enalapril Tablets was approximately USD 28.60 million as of MAT December 2024. Data from Symphony, a specialty data aggregator, places the market size at around USD 109.24 million as of MAT March 2025. The variation in estimates is attributed to differing data methodologies and sources. The acquisition by SPL will be financed using proceeds from the company's recent Initial Public Offering (IPO), aligning with the intended use of funds outlined in the Red Herring Prospectus filed during the IPO process. About Senores Pharmaceuticals Limited Senores Pharmaceuticals Limited is a research-focused pharmaceutical company engaged in the development and manufacturing of a diverse portfolio of pharmaceutical products. The company, along with its subsidiaries, serves regulated and emerging markets including the United States and Canada, with a focus on various therapeutic segments and dosage forms. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
17-05-2025
- Business
- Time of India
PU files patents for green nanoplatform in skincare and pharma
Chandigarh: Panjab University has filed Indian and international patents for a new green nanomicelle platform developed by Professor Indu Pal Kaur and her PhD scholars Bakr Ahmed and Simrandeep Kaur. The solvent-free, eco-friendly technology enables targeted delivery of sensitive bioactives such as peptides, herbal extracts, cannabinoids, vitamins, proteins, and small molecules. These components have applications in pharmaceuticals, nutraceuticals, cosmetics, paediatrics, veterinary care, and wellness products. The platform is scalable and designed for clean-label processes, with formulations developed at room temperature. Minimal use of USFDA-approved solvents is allowed to accommodate poorly soluble actives without compromising safety or scalability. The technology has already been transferred to an industrial partner for skincare and cosmetics applications, marking a key step in academia-industry collaboration. Professor Indu Pal Kaur, who leads the IPK Lab at Panjab University, described the innovation as affordable and adaptable, supporting both MSMEs and global companies in developing safe and sustainable products. Her lab focuses on turning research challenges into practical solutions, with a strong emphasis on long-term partnerships and technology transfer. The university's Centre for Industry-Institute Partnership Programme, established in 1996, plays a vital role in fostering innovation through revenue-sharing models between faculty and the institution. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo Panjab University vice-chancellor Renu Vig said the university takes pride in translating research into industry-relevant innovations that improve lives and enhance its academic reputation. With more than 22 patents granted and 17 filed, Professor Kaur's work highlights the growing importance of intellectual property in India's innovation ecosystem.
